Pharma: Is the pandemic investment template about to play out?

The return of the flu season in India and the US, and COVID-19 in China sparked more investor interest in the sector.

Solara Active: Aurore deal to act as a booster for CRAMS; accumulate

The Aurore deal should help Solara in ramping up CRAMS portfolio, diversifying the API product basket and also aiding backward integration

Buy Solara Active Pharma Sciences: target of Rs 1730: Sharekhan

Sharekhan is bullish on Solara Active Pharma Sciences has recommended buy rating on the stock with a target price of Rs 1730 in its research report dated April 12, 2021.

Buy Solara Active Pharma Sciences; target of Rs 1700: Sharekhan

Sharekhan is bullish on Solara Active Pharma Sciences has recommended buy rating on the stock with a target price of Rs 1700 in its research report dated February 03, 2021.

Buy Solara Active Pharma Sciences: target of Rs 1450 : Sharekhan

Sharekhan is bullish on Solara Active Pharma Sciences recommended buy rating on the stock with a target price of Rs 1450 in its research report dated December 08, 2020.

Buy Solara Active Pharma Sciences: target of Rs 1371: Sharekhan

Sharekhan is bullish on Solara Active Pharma Sciences recommended buy rating on the stock with a target price of Rs 1371 in its research report dated October 30, 2020.

Buy Solara Active Pharma Sciences; target of Rs 1371: Sharekhan

Sharekhan is bullish on Solara Active Pharma Sciences recommended buy rating on the stock with a target price of Rs 1371 in its research report dated October 30, 2020.

Solara Active: Broadening of portfolio to be a re-rating catalyst

Solara is on the verge of transforming its business profile. It is looking at utilising cash flows to build project pipeline for CRAMS, investment behind technology platforms and looking for inorganic opportunities

Solara Active: Strong execution, but valuations fair

Among the risk factors to track for Solara Active are elevated pledge percentage for promoters which is 51 percent of their shareholdings

Weekly Tactical Pick | Solara Active Pharma Sciences

The stock rides on many tailwinds: business growth opportunity, innovation pipeline and its strong operating performance

Solara Active Q2 serves a strong dose, new molecules key trigger

Ranitidine controversy: Which Indian pharma companies stand to lose?

This pure API play gains strength on improving product mix

Ideas for Profit | An API company that combines good growth prospects with reasonable valuations